您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
NA/LE Rat anti-mouse IL-4 Recombinant mAb (S-R379)

NA/LE Rat anti-mouse IL-4 Recombinant mAb (S-R379)

货号: S0B0839
价格: 700
规格: 1mg
介绍: -
其他: -
产品规格
  • 宿主来源

    Rat
  • 抗原名称

    IL-4
  • 分子别名

    Interleukin-4, B-cell IgG differentiation factor, B-cell growth factor 1, B-cell stimulatory factor 1 (BSF-1), IGG1 induction factor, Lymphocyte stimulatory factor 1
  • Accession

    P07750
  • 克隆号

    S-R379
  • 抗体类型

    Recombinant mAb
  • 抗体同种型

    Rat IgG1,k
  • 应用

    Neutralization
  • 反应种属 ?

    Ms
  • 浓度

    4mg/ml
  • 内毒素含量

    <1EU/mg
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    PBS pH7.4, containing no preservative

  • 储存条件

    2 to 8 °C for 2 weeks under sterile conditions;

    -20 °C for 3 months under sterile conditions; 

    -80 °C for 24 months under sterile conditions.

    Please avoid repeated freeze-thaw cycles.

  • 稀释度

背景介绍
  • IL-4, also known as Interleukin-4, is a cytokine (a type of signaling protein) that plays a crucial role in the immune system. It is produced by several types of immune cells, including T helper cells (Th2 cells), mast cells, eosinophils, and basophils. IL-4 is a key player in the development of allergic responses. It stimulates B cells to produce IgE antibodies, which are involved in allergic reactions such as asthma, atopic dermatitis, and allergic rhinitis. IL-4 is essential for the differentiation and polarization of T helper cells into Th2 cells. Th2 cells produce cytokines that promote humoral immunity and allergic responses. IL-4 can regulate the production of other cytokines, including IL-5, IL-13, and granulocyte-macrophage colony-stimulating factor (GM-CSF). These cytokines further contribute to allergic and inflammatory responses. Although IL-4 is primarily associated with allergic responses, it has also been implicated in the development of certain autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Due to its key role in allergic and inflammatory responses, IL-4 has been a target for therapeutic intervention. Blocking the effects of IL-4 or its receptor (IL-4R) has shown promise in treating allergic diseases in preclinical and clinical studies.